CELCUITY INC (CELC)
Sector: Health Care
2026 Annual Meeting Analysis
CELCUITY INC · Meeting: May 14, 2026
Directors FOR
7
Directors AGAINST
1
Say on Pay
FOR
Auditor
FOR
Director Elections
Election of Directors
Against Analysis
Dr. Laing is the brother-in-law of CEO Brian F. Sullivan, representing a direct familial relationship with the most senior executive at the company; under the voting policy, a director with a familial relationship to the CEO warrants a vote against regardless of the director's qualifications or the company's stock performance.
For Analysis
Director since 2019 with strong oncology drug development credentials; no overboarding, attendance, or independence issues; TSR trigger does not apply as Celcuity's 3-year return of +992.4% outpaces XBI (SPDR S&P Biotech ETF) by +924.2 percentage points, well above the 65pp threshold required to trigger a vote against.
Director since 2014 with relevant venture capital and corporate finance experience; audit committee financial expert designation; no overboarding, attendance, or independence issues; TSR trigger does not apply given Celcuity's exceptional outperformance of XBI (SPDR S&P Biotech ETF).
Director since 2019 with relevant biomedical and diagnostics expertise; no overboarding, attendance, or independence issues; TSR trigger does not apply as Celcuity's 3-year return far exceeds the XBI (SPDR S&P Biotech ETF) benchmark by +924.2 percentage points.
Director since 2022 with extensive pharmaceutical commercialization experience; no overboarding, attendance, or independence issues; TSR trigger does not apply given Celcuity's massive outperformance of XBI (SPDR S&P Biotech ETF) over the 3-year period.
Director since 2017 with deep public accounting and financial expertise; designated audit committee financial expert; no overboarding, attendance, or independence issues; TSR trigger does not apply as Celcuity outperformed XBI (SPDR S&P Biotech ETF) by +924.2 percentage points over 3 years.
Appointed February 2026 and therefore within the 24-month new-director exemption period, making him automatically exempt from the TSR performance trigger; brings relevant oncology commercialization experience from Seagen and Genentech.
Co-founder and CEO serving as director since 2012; as an executive director he is subject to the same TSR trigger as all others, but that trigger clearly does not apply given Celcuity's 3-year return of +992.4% which outpaces XBI (SPDR S&P Biotech ETF) by +924.2 percentage points, far above the 65pp threshold; no overboarding or attendance issues identified.
Seven of the eight director nominees receive a FOR vote; Dr. Lance Laing receives an AGAINST vote solely due to his familial relationship (brother-in-law) with CEO Brian Sullivan, which under the voting policy is a categorical disqualifying factor for directors with family ties to the most senior executive; the TSR performance trigger does not apply to any director because Celcuity's 3-year return of +992.4% outperforms the XBI (SPDR S&P Biotech ETF) by +924.2 percentage points, well above the 65pp threshold applicable when absolute returns exceed +20%.
Say on Pay
✓ FORCEO
Brian F. Sullivan
Total Comp
$16,373,868
Prior Support
N/A
The CEO's total reported compensation of $16.4 million is dominated by stock option awards ($15.4 million, or about 94% of total), giving the program an extremely high variable/performance-based pay mix that well exceeds the 50-60% policy threshold; this is appropriate for a pre-revenue clinical-stage biotech company whose executives are compensated largely through equity that only delivers value if the stock price rises. The pay-for-performance alignment is strong: Celcuity's stock rose approximately 612% from end of 2022 to end of 2025, and the 3-year return of +992.4% massively outpaces the XBI (SPDR S&P Biotech ETF) benchmark by over 900 percentage points, meaning the above-benchmark equity grants were fully justified by exceptional shareholder returns. The company also has a clawback policy in place and a formal change-in-control severance plan, and performance goals under the 2025 annual incentive plan were assessed as achieved at 106%, supporting a FOR vote.
Auditor Ratification
✓ FORAuditor
Boulay PLLP
Tenure
N/A
Audit Fees
$301,020
Non-Audit Fees
$10,015
Non-audit fees (tax services of $10,015) represent only about 3.3% of audit fees ($301,020), far below the 50% threshold that would trigger a concern; auditor tenure is not disclosed in the proxy so the tenure trigger cannot fire per policy; no material restatements are disclosed; Boulay is an appropriately sized firm for a clinical-stage biotech company at this market cap level.
Overall Assessment
This is a largely routine annual meeting ballot for Celcuity, a clinical-stage biotech company that delivered extraordinary stock performance over the past three years; the key exception is a vote against Dr. Lance Laing's re-election as a director due to his familial relationship (brother-in-law) with CEO Brian Sullivan, which is a categorical governance concern under the voting policy regardless of company performance or individual qualifications. All other standard proposals — the director slate, auditor ratification, and Say on Pay — receive a FOR vote, supported by Celcuity's exceptional 992% three-year total return that far outpaces the XBI (SPDR S&P Biotech ETF) benchmark and a compensation structure that is heavily weighted toward performance-linked equity.